Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Myriad Options for Molecular Diagnostics
As Technology Advances through the Clinical Arena, Costs Are Lowered and Time Is Saved
- Biomarkers save money. That simple fact, coupled with a wealth of information to link specific diseases to particular biomarkers, is resulting in explosive growth for molecular diagnostics. “Molecular diagnostics is proving it can significantly lower the cost and overall Leomics Associates and scientific advisor for CytoCare. Starting patients ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.